Prostata - Karzinom: Taxan - Studien
Allgemeines
Eine Chemotherapie mit Docetaxel kann die Überlebenszeit eines metastasierten HRPCs verlängern (1: Metaanalyse).
Studien
| Studie | Rekrutierung | Patienten | Kontroll-Arm | Prüf-Arm | Bemerkungen |
| GETUG-12 (6,7) | 2002–2006 | 413 | Goserelin 10,8 mg alle 3M 3a | + Docetaxel 70 mg/qm 4x + Estramustin | M0 |
| TAX 3501 (8) | 2005–2007 | 228 | Leuprolide 22,5 mg alle 3M 18M | + Docetaxel 75 mg/qm 6x | M0 |
| RTOG 0521 (9) | 2005–2009 | 612 | LHRH + Antiandrogen + RT) | + Docetaxel 75 mg/qm 6x + Prednison | M0 |
| STAMPEDE (+-docetaxel) (3) | 2005–2013 | 1776 | ADT + RT | + Docetaxel 75 mg/qm 6x + Predison | M0 und M1 |
| STAMPEDE (zoledron +- docetaxel) (3) | 2005–2013 | 1186 | ADT + RT + Zoledro 4 mg alle 3-4W 2a | + Docetaxel 75 mg/qm 6x | M0 und M1 |
| GETUG-15 (4,5) | 2004–2008 | 385 | LHRH oder Kastration oder duale Blockade | + Docetaxel 75 mg/qm bis 9x | M1 |
| CHAARTED (2) | 2006–2012 | 790 | LHRH oder Kastration | + Docetaxel 75 mg/qm 6x | M1 |
Quelle
1.) Vale CL, et al., for the STOpCaP Steering Group:
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer:
a systematic review and meta-analyses of aggregate data.
Lancet Oncol 2016;17):243–256. Doi: 10.1016/S1470-2045(15)00489-1
2.) Sweeney CJ, Chen Y-H, Carducci M:
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
N Engl J Med. 2015;373:737–746
3. ) James ND, Sydes MR, Clarke NW:
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE):
survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet 2015 http://dx.doi.org/10.1016/S0140-6736(15)01037-5
4.) Gravis G, Fizazi K, Joly F:
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2013;14:149–158
5.) Gravis G, Boher JM, Joly F:
Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa):
long-term analysis of the GETUG-AFU 15 phase III trial.
Proc Am Soc Clin Oncol. 2015;33(suppl 7) abstr 140.
6.) Fizazi K, Laplanche A, Lesaunier F:
Docetaxel-estramustine in localized high-risk prostate cancer: results of the French Genitourinary Tumor Group GETUG 12 phase III trial.
Proc Am Soc Clin Oncol. 2014;32(suppl) abstr 5005.
7.) Fizazi K, Faivre L, Lesaunier F:
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12):
a phase 3 randomised controlled trial.
Lancet Oncol. 2015;16:787–794
8.) Schweizer MT, Huang P, Kattan MW, Kibel AS, De Wit R, Sternberg CN:
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501).
Cancer. 2013;119:3610–3618
9.) Sandler HM, Hu C, Rosenthal SA:
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT)
with doxetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521)
Proc Am Soc Clin Oncol. 2015;33(suppl) abstr LBA5022.
